Hrishi Patel, MD
Internal Medicine · Hinton, WVNPI 1306812680
Payments from drug & device makers
Across 77 payments — averaging $18.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$251
- GSK$155
- Exact Sciences$107
- Novartis$104
- Novo Nordisk$96
- Merck$85
- plus $633 from 21 others
What the payments were for
- Food & beverage$1,431100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 11 | $251 |
| GSK | 9 | $155 |
| Exact Sciences | 5 | $107 |
| Novartis | 6 | $104 |
| Novo Nordisk | 6 | $96 |
| Merck | 5 | $85 |
| Amgen | 5 | $80 |
| Lilly USA, LLC | 4 | $78 |
| Boehringer Ingelheim | 4 | $71 |
| Pfizer | 3 | $46 |
| Astellas Pharma US Inc | 1 | $33 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $33 |
| Boston Scientific | 1 | $25 |
| Aimmune Therapeutics, Inc. | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $24 |
| Biogen | 1 | $23 |
| La Jolla Pharmaceutical Company | 1 | $21 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
| Vertex | 1 | $19 |
| Scilex Pharmaceuticals Inc. | 1 | $19 |
| Abbott | 1 | $19 |
| AstraZeneca | 1 | $18 |
| Dexcom, Inc. | 1 | $18 |
| Phathom Pharmaceuticals, Inc. | 1 | $18 |
| Biodelivery Sciences International, Inc. | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $14 |
| Collegium Pharmaceutical, Inc. | 1 | $14 |
How this compares
$1,431 in reported general payments places this provider in the 75th percentile of 573 internal medicine providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 128 | $179,203 |
| JardianceEmpagliflozin | 83 | $108,303 |
| EliquisApixaban | 104 | $101,529 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 93 | $67,806 |
| EntrestoSacubitril/Valsartan | 21 | $33,994 |
| TradjentaLinagliptin | 47 | $31,812 |
| BrilintaTicagrelor | 46 | $31,588 |
| JanuviaSitagliptin Phosphate | 20 | $27,467 |
| XareltoRivaroxaban | 21 | $26,898 |
| Tresiba Flextouch U-200Insulin Degludec | 28 | $23,223 |
| LinzessLinaclotide | 19 | $22,977 |
| FarxigaDapagliflozin Propanediol | 14 | $20,460 |
| MounjaroTirzepatide | 19 | $20,004 |
| Breo ElliptaFluticasone/Vilanterol | 35 | $15,465 |
| BelbucaBuprenorphine Hcl | 11 | $9,647 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $96 | $179,203128 claims |
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat | $71 | $148,139147 claims |
| PfizerEliquis | $46 | $101,529104 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $155 | $87,453140 claims |
| AstraZenecaBrilinta, Farxiga, Symbicort | $18 | $60,52096 claims |
| NovartisEntresto | $104 | $33,99421 claims |
| AbbVieLinzess, Restasis | $251 | $30,52535 claims |
| MerckJanuvia | $85 | $27,46720 claims |
| Lilly USA, LLCMounjaro | $78 | $20,00419 claims |
| Collegium Pharmaceutical, Inc.Belbuca | $14 | $9,64711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 573 internal medicine providers in West Virginia.
Other internal medicine in Hinton
- Ward PaineMorgantown$5.1M
- William ChapmanCharleston$1.7M
- Mustafa AwiliHuntington$906K
- David PickeringParkersburg$694K
- Laura DavissonMorgantown$118K
- Michael BrumageClendenin$87K
- Govind PatelFairmont$59K
- Lynn SmithLewisburg$31K
- Bisher MustafaHuntington$28K
- Johny AlencherryMartinsburg$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.